Biotest shares fall as it sells US therapy business assets

23 January 2017

Germany’s Biotest (BIO: Xetra) saw its shares fall 4.9% to 16.60 euros in late afternoon trading, after it announced its US subsidiary, Biotest P Saveharmaceuticals Corp (BPC), was selling certain assets of its US therapy business to ADMA Biologics.

Included in the assets to be transferred at closing are BPC's plasma fractionation facility, its commercial products, contract manufacturing agreements as well as BPC's Boca Raton, Florida headquarters and real properties.

Upon closing of this transaction, Biotest will receive equity interest in ADMA's issued and outstanding capital stock in the form of 50% minus one share representing 25% of the voting rights. In addition, Biotest will:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK